Investors bought shares of Bristol-Myers Squibb Co (NYSE:BMY) on weakness during trading on Wednesday. $73.35 million flowed into the stock on the tick-up and $43.76 million flowed out of the stock on the tick-down, for a money net flow of $29.59 million into the stock. Of all companies tracked, Bristol-Myers Squibb had the 24th highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.05) for the day and closed at $66.63
A number of research analysts have recently commented on BMY shares. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price objective for the company. in a research report on Thursday, December 28th. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $51.56 to $78.00 in a research report on Thursday, February 15th. BMO Capital Markets reaffirmed a “sell” rating and set a $52.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Finally, Leerink Swann upped their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $66.30.
The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The stock has a market cap of $109,420.00, a PE ratio of 28.23, a PEG ratio of 2.07 and a beta of 0.98.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.40%. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.
In other news, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of BMY. Advisor Partners LLC grew its stake in shares of Bristol-Myers Squibb by 6.9% during the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock valued at $2,356,000 after purchasing an additional 2,382 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of Bristol-Myers Squibb by 2.5% during the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after purchasing an additional 8,813 shares during the last quarter. Israel Discount Bank of New York grew its stake in shares of Bristol-Myers Squibb by 31.8% during the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock valued at $586,000 after purchasing an additional 2,540 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Bristol-Myers Squibb by 0.7% during the third quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after purchasing an additional 5,451 shares during the last quarter. Finally, Aperio Group LLC grew its stake in shares of Bristol-Myers Squibb by 12.7% during the third quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock valued at $54,463,000 after purchasing an additional 96,561 shares during the last quarter. 71.55% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This article was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3262266/traders-buy-shares-of-bristol-myers-squibb-bmy-on-weakness-2.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.